Literature DB >> 22005198

FoxO4 inhibits atherosclerosis through its function in bone marrow derived cells.

Min Zhu1, Qing-Jun Zhang, Lin Wang, Hao Li, Zhi-Ping Liu.   

Abstract

OBJECTIVES: FoxO proteins are transcription factors involved in varieties of cellular processes, including immune cell homeostasis, cytokine production, anti-oxidative stress, and cell proliferation and differentiation. Although these processes are implicated in the development of atherosclerosis, very little is known about the role of FoxO proteins in the context of atherosclerosis. Our objectives were to determine whether and how inactivation of Foxo4, a member of the FoxO family, in vivo promotes atherosclerosis. METHODS AND
RESULTS: Apolipoprotein E-deficient (apoE(-/-)) mice were crossbred with animals lacking Foxo4 (Foxo4(-/-)). After 10 weeks on a high fat diet (HFD), Foxo4(-/-)apoE(-/-) mice showed elevated atherosclerosis and increased amount of macrophages and T cells in the plaque compared to apoE(-/-) mice. Bone marrow transplantations of chimeric C57B/6 mice reconstituted with either wild-type or Foxo4(-/-) bone marrows indicate that Foxo4-deficiency in bone marrow derived cells sufficiently promoted atherosclerosis. Foxo4-null macrophages produced elevated inflammatory cytokine IL-6 and levels of reactive oxygen species (ROS) in response to lipopolysaccharides in vitro. Serum levels of IL-6 were upregulated in HFD-fed Foxo4(-/-)apoE(-/-) mice compared to those of apoE(-/-) mice.
CONCLUSIONS: FoxO4 inhibits atherosclerosis through bone marrow derived cells, possibly by inhibition of ROS and inflammatory cytokines that promote monocyte recruitment and/or retention.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22005198      PMCID: PMC3226872          DOI: 10.1016/j.atherosclerosis.2011.09.038

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  45 in total

Review 1.  The genetics of ageing.

Authors:  Cynthia J Kenyon
Journal:  Nature       Date:  2010-03-25       Impact factor: 49.962

Review 2.  Role of nuclear factor kappaB in cardiovascular health and disease.

Authors:  Kim Van der Heiden; Simon Cuhlmann; Le A Luong; Mustafa Zakkar; Paul C Evans
Journal:  Clin Sci (Lond)       Date:  2010-02-23       Impact factor: 6.124

Review 3.  The FoxO family in cardiac function and dysfunction.

Authors:  Sarah M Ronnebaum; Cam Patterson
Journal:  Annu Rev Physiol       Date:  2010       Impact factor: 19.318

Review 4.  The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation.

Authors:  Allan R Brasier
Journal:  Cardiovasc Res       Date:  2010-03-03       Impact factor: 10.787

Review 5.  Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease.

Authors:  Benjamin Sadowitz; Kristopher G Maier; Vivian Gahtan
Journal:  Vasc Endovascular Surg       Date:  2010-05       Impact factor: 1.089

6.  Increased oxidative stress in atherosclerosis-predisposed regions of the mouse aorta.

Authors:  Mehran Haidari; Muzammil Ali; Leila Gangehei; Mian Chen; Wei Zhang; Myron I Cybulsky
Journal:  Life Sci       Date:  2010-06-08       Impact factor: 5.037

Review 7.  Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies.

Authors:  Roland Klingenberg; Göran K Hansson
Journal:  Eur Heart J       Date:  2009-10-30       Impact factor: 29.983

Review 8.  The discovery of cellular immunity in the atherosclerotic plaque.

Authors:  Göran K Hansson; Lena Jonasson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-11       Impact factor: 8.311

Review 9.  Adaptive immunity and atherosclerosis.

Authors:  John Andersson; Peter Libby; Göran K Hansson
Journal:  Clin Immunol       Date:  2009-07-26       Impact factor: 3.969

10.  JNK/FOXO-mediated neuronal expression of fly homologue of peroxiredoxin II reduces oxidative stress and extends life span.

Authors:  Kyu-Sun Lee; Kanae Iijima-Ando; Koichi Iijima; Won-Jae Lee; Joon H Lee; Kweon Yu; Dong-Seok Lee
Journal:  J Biol Chem       Date:  2009-08-31       Impact factor: 5.157

View more
  8 in total

1.  FoxO4 promotes early inflammatory response upon myocardial infarction via endothelial Arg1.

Authors:  Min Zhu; Sean C Goetsch; Zhaoning Wang; Robert Luo; Joseph A Hill; Jay Schneider; Sidney M Morris; Zhi-Ping Liu
Journal:  Circ Res       Date:  2015-10-05       Impact factor: 17.367

2.  FoxO4 promotes myocardial ischemia-reperfusion injury: the role of oxidative stress-induced apoptosis.

Authors:  Lingling Yu; Weifang Zhang; Chahua Huang; Qian Liang; Huihui Bao; Zhijian Gong; Minxuan Xu; Zhenzhen Wang; Minhua Wen; Xiaoshu Cheng
Journal:  Am J Transl Res       Date:  2018-09-15       Impact factor: 4.060

Review 3.  Role of insulin action in the pathogenesis of diabetic complications.

Authors:  Kyoichiro Tsuchiya
Journal:  Diabetol Int       Date:  2022-09-07

4.  Expanded granulocyte/monocyte compartment in myeloid-specific triple FoxO knockout increases oxidative stress and accelerates atherosclerosis in mice.

Authors:  Kyoichiro Tsuchiya; Marit Westerterp; Andrew J Murphy; Vidya Subramanian; Anthony W Ferrante; Alan R Tall; Domenico Accili
Journal:  Circ Res       Date:  2013-02-18       Impact factor: 17.367

5.  OutFOXing myeloid cells in atherosclerosis with FoxOs.

Authors:  Mark W Feinberg
Journal:  Circ Res       Date:  2013-03-29       Impact factor: 17.367

6.  Mitochondria and FOXO3: breath or die.

Authors:  Judith Hagenbuchner; Michael J Ausserlechner
Journal:  Front Physiol       Date:  2013-06-20       Impact factor: 4.566

7.  MicroRNA-328-3p Protects Vascular Endothelial Cells Against Oxidized Low-Density Lipoprotein Induced Injury via Targeting Forkhead Box Protein O4 (FOXO4) in Atherosclerosis.

Authors:  Xiaowei Qin; Jiantao Guo
Journal:  Med Sci Monit       Date:  2020-04-24

Review 8.  Long live FOXO: unraveling the role of FOXO proteins in aging and longevity.

Authors:  Rute Martins; Gordon J Lithgow; Wolfgang Link
Journal:  Aging Cell       Date:  2015-12-08       Impact factor: 9.304

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.